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Abstract 
This paper presents a new method for site-specific labelling of antibodies employing enzymatic reactions without oxidizing or reducing agents. IgG 
was first treated with immobilized sialidase from Clostridium perfringens to cleave bound NeuAc. CMP-9-deoxy-9-salizoyl-NeuAc, an activated sialic 
acid analogue, was labelled with 13’1 via the iodogen-method in high yields (>95%). Then the oligosaccharide chains of antibodies were labelled yield 
with the radioactive NeuAc analogue by transfer using a-2,6-sialyltransferase from rat liver in 50%. 
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1. Introduction 
During the past decades different methods for the ra- 
dioactive labelling of antibodies were developed. La- 
belled antibodies are indispensible as tools in medicine 
and biochemistry. For each application the immunoreac- 
tivity of the antibody plays a decisive role. Therefore, the 
development of mild reaction conditions for the labelling 
is of great importance. Besides the random labelling 
methods, reactions were developed for labelling outside 
of the antibodies binding site. In those studies two func- 
tional groups are involved, the disulphide bridges be- 
tween the polypeptide chains and the oligosaccharide 
residues on the Fc-part. In the first procedure, a breaking 
of disulphide bridges is necessary to obtain thiol groups 
for the reaction with bifunctional agents [l-3]. The sec- 
ond method is based on oxidation of the saccharide res- 
idues to aldehyde groups and subsequent reaction with 
bifunctional reagents [4-61. Both conversions influence 
the immunological properties in a special manner. 
In this paper we describe a new way for the labelling 
by enzymatic transfer of synthetic sialic acid derivatives 
onto the oligosaccharide chains of antibodies. The ad- 
vantage of these enzymatic reactions is the absence of 
*Corresponding authors. 
Abbreviations: NeuAc, N-acetyl-D-neuraminic acid; CMP-NeuAc, 
cytidine-5’-monophospho-NeuAc; a-2,6-ST, p-o-galactosyl-l,CN-ace- 
tyl-~-o-glucosamine-a-2,6-N-acetylneuraminyl~ransferase rom rat 
liver (E.C. 2.4.99.1); iodogen, 1,3,4,6-tetrachloro-3a,6a_diphenylglycol- 
uril. 
oxidizing and reducing agents which guarantees that the 
antibody structure remains intact. Sialic acids were 
found in terminal position of oligosaccharide chains of 
many glycoproteins such as antibodies [7,8]. The en- 
zymes for cleavage (sialidase), activation (CMP-NeuAc 
synthase) and transfer (sialyltransferase) of sialic acid 
are available. Several studies with sialyltransferase dem- 
onstrated, that differently substituted NeuAc, e.g. 9- 
amino-9-deoxy-NeuAc and 9-fluoresceinyl-9-deoxy- 
NeuAc can be transferred onto oligosaccharide chains of 
glycoproteins [9-161. 
2. Materials and methods 
2.1. 14C measuremenf 
CMP-Nacetyl[4,5,6,7,8,9-“‘Clneuraminic a id was obtained from 
Amersham-Buchler. After the reaction, the mixture was separated by 
gel chromatography and measured with Ready Cups (Beckmann) by 
a liquid scintillation counter 1215 Rackbeta (LKB Packard). CMP-9- 
salizoyl-9-deoxy-NeuAc was obtained by reaction of CMP-Pdeoxy-9- 
amino-NeuAc [13] with the N-succinimidester of salicylic acid. The 
detailed synthesis will be described elsewhere. 
2.2. “*I iodination 
The standard reaction mixture contained 1 mg CMP-9-deoxy-Psal- 
izoyl-NeuAc in 50 mM phosphate buffer pH 7.0. The reaction vials 
were coated with different quantities of iodogen (Serva). The yield of 
the labelling reaction was determined by HPLC. 
2.3. Chromatography systems 
We used a HPLC-system (Merck-Hitachi) with a radioactivity de- 
tector LB 507 (Berthold). Chromatography was performed employing 
a column (15 x 1 cm) of the tentacle ion exchanger EMD TMAE (650) 
S (MCerck) which was eluted (2 ml/min) with a saline gradient from 
0.1 M to 0.7 M containing 15 mM phosphate buffer pH 7.0 within 20 
min. 
0014-5793/94/%7.00 0 1994 Federation of European Biochemical Societies. All rights reserved. 
SSDI 0014-5793(93)El444-Q 
214 II. Schwarz et al. IFEBS Letters 337 (1994) 213~ 216 
Fig. 1. Transfer of [14C]NeuAc onto IgG after different times of incu- 
bation with neuraminidase. 
I 5,25 
Reaction time of (x-2,6-sialyltransferase (h) 
Fig. 2. Introduction of [‘%]NeuAc into IgG in dependence on transfer 
time. 
For gel chromatography a standard system (Pharmacia) with a Seph- 
adex G-50 column (20 x 1 cm) was used. 
2.4. Enzymatic assays 
Desialylation of human IgG was performed at room temperature in 
50 mM acetate buffer at pH 5.5 employing immobilized CIostridizun 
perfringens sialidase (E.C. 3.2.1.18) (Sigma). The reaction mixture con- 
tained 0.2 units of enzyme per milligram IgG and was dialyzed against 
50 mM acetate buffer at pH 5.5. Incubation was terminated by centrif- 
ugation of the enzyme. 
Transfer of the NeuAc-analogues was catalyzed by a-2,6-sialyltrans- 
ferase (a-2,6-ST) from rat liver (Boehringer Mannheim). For transfer 
of 14C labeled NeuAc 50 mg IgG, 4.9 x lo-” mol [‘%]CMP-NeuAc and 
10 mU a-2,6-ST were incubated. 
For the transfer of the monoiodo derivative of CMP-9-deoxy-9- 
salizoyl-NeuAc 100 mg IgG in 100 ml 15 mM phosphate buffer, pH 7.0, 
10 mU a-2,6-ST (5 ml) and 100 ml of the HPLC-fraction containing the 
radioactive substance were incubated. The reaction mixture for the 
transfer of the diiodo derivative consisted of 100 mg IgG in 100 ml 15 
mM phosphate buffer pH 7.0, 40 mU a-2,6-ST (20 ml) and 200 ml of 
the HPLC-fraction containing the diiodo derivative. 
3. Results and discussion 
First we studied the reaction conditions for preparing 
asialo-IgG and the subsequent ransfer of [14C]NeuAc 
from the CMP-activated compound. Labelling of IgG 
without pretreatment with neuraminidase was very small 
(CO.Ol%). Therefore, IgG was incubated with 0.2 units 
of immobilized neuraminidase per milligram protein. 
After different periods of time aliquots of IgG were 
treated with ol-2,6-ST and [14C]CMP-NeuAc. The results 
show that under these conditions one hour of incubation 
was sufficient for the removal of protein-bound sialic 
acid (Fig. 1). 
Studying the time-dependence of [14C]NeuAc transfer 
we found one hour sufficient o label the desialylated IgG 
(Fig. 2). 
Next we labeled CMP-9-deoxy-9-salizoyl-NeuAc with 
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Fig. 3. HPLC-chromatogram of the reaction products 1, 2, and 3 after 
13’1 iodination of CMP-9-salizoyl-NeuAc by iodogen. 
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Fig. 4. Time-dependence of the 13’1 iodination of CMP-9-deoxy-9-sal- 
izoyl-NeuAc on two different amounts of iodogen. 0, 1 mg iodogen; 
q , 10 mg iodogen. 
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Influence of different amounts of carrier on the ratio of the 
reaction products obtained by “‘I iodination of CMP-9-salizoyl- 
NeuAc. q , CMP-9-salizoyl-Net&; 0, sum of product 1 and 2; x, 
product 3. 
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Fig. 6. Dependence of the “‘I iodination of CMP-9-salizoyl-NeuAc 
(carrier added reaction) on the pH-value. 0, monoiodinated products; 
q , diiodinated product. 
1311 via the iodogen-method [7]. This procedure was pre- 
ferred because it is aC solid phase reaction. After sepa- 
ration from the iodogen-coated vial the reaction mixture 
contained only the starting materials and iodinated 
products without oxidizing or reducing agents. 
s 60 
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Applying HPLC we found three different radioactive 
products (Fig. 3). Products 1 and 2 were obtained by 
reaction with carrier-free i3iI solution, product 3 by the 
addition of a carrier KI. The latter one has a higher 
specific radioactivity than the others. Therefore, appar- 
ently 1 and 2 are two different monoiodinated erivatives 
whereas 3 is diiodinated. 
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Iodination of the activated sialic acid analogue Fig. 8. Transfer of product 3 onto asialo-IgG by a-2,6_sialyltransferase. 
showed, that the reaction with 1 or 10 mg iodogen was 
very fast and complete within a few seconds (Fig. 4). 
For carrier added iodination we used vials with 100 
mg iodogen. Under these conditions the reaction was 
complete at the same short time. Addition of different 
amounts of carrier iodide produced different ratios of the 
three reaction products. As expected, by addition of ex- 
cess KI only diiodinated sialic acid analogue, product 3, 
was formed (Fig. 5). This result confirms the formation 
of two different monoiodinated and one diiodinated 
products. In all these labelling reactions no decomposi- 
tion of the CMP-9-deoxy-9-salizoyl-NeuAc by iodogen 
was observed. 
Further, the dependence of the iodogen reaction on 
the pH was studied. The reaction was complete in the 
pH-range 6 to 8 (Fig. 6). At lower pH we found only 
monoiodinated products and free iodine whereas a 
higher pH caused decomposition giving undefined radio- 
active and nonradioactive products. 
Transfer of 13’1 labelled CMP-9-deoxy-9-salizoyl- 
NeuAc: two 13’1 labelled products were transfered onto 
human IgG. Fig. 7 shows the transfer of product 1, Fig. 
8 the transfer of product 3. The reason for the difference 
in reaction velocity and yield may be a different kinetics 
of the a-2,6-ST for the two substrates and the different 
ratio between a-2,6-ST, IgG and the iodinated product. 
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Fig. 7. Transfer of product 1 onto asialo-IgG by a-2,6_sialyltransferase. 
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In this study we present a new method for site-specific 
labelling of antibodies by enzymatic transfer of radioac- 
tive NeuAc analogues, thus avoiding the use of oxidizing 
or reducing agents. Labelling of CMP-9-salizoyl-NeuAc 
with radioactive iodine isotopes can be rapidly per- 
formed by the iodogen method with high yields. 
We are presently investigating the possibility of em- 
ploying this method to label biomolecules with other 
radionuclides. 
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